Citations

Clear

10 citation(s) found for "Sullivan, Daniel".

Magnetic resonance biomarkers in radiation oncology: The report of AAPM Task Group 294
McGee, Kiaran P. , Hwang, Ken‐Pin, Sullivan, Daniel C. , Hu, Yanle , Debbins, Josef P., Paulson, E.S. , Olsen, Jeffrey R., Hua, Chia‐Ho , Warner, Lizette, Tyagi, Neelam , Chung, Caroline , Kurhanewicz, John V. , Wang, Jihong , Li, Wen , Daniel, J. , Moros, Eduardo G.

Mayo Clinic

Medical Physics | April 17, 2021 | Volume: 48 | Issue: 7 | Pages: No page available

10.1002/mp.14884 | PMID 33864283 Get It

PurposeA magnetic resonance (MR) biologic marker (biomarker) is a measurable quantitative characteristic that is an indicator of normal biological and pathogenetic processes or a response to therapeutic intervention derived from the MR imaging process. There is significant potential for MR biomarkers to facilitate personalized approaches to cancer care through more precise disease targeting by quantifying normal versus pathologic tissue function as well as toxicity to both radiation and chemotherapy. Both of which have the potential to increase the therapeutic ratio and provide earlier, more accurate monitoring of treatment response. The ongoing integration of MR into routine clinical radiation therapy (RT) planning and the development of MR guided radiation therapy systems is providing new opportunities for MR biomarkers to personalize and improve clinical outcomes. Their appropriate use, however, must be based on knowledge of the physical origin of the biomarker signal, the relationship to the underlying biological processes, and their strengths and limitations. The purpose of this report is to provide an educational resource describing MR biomarkers, the techniques used to quantify them, their strengths and weakness within the context of their application to radiation oncology so as to ensure their appropriate use and application within this field.
Phase I trial of obatoclax mesylate in combination with bortezomib for treatment of relapsed multiple myeloma.
Stewart, A. Keith, Trudel, Suzanne , Zonder, Jeffrey A. , Hayman, Suzanne R. , Erlichman, Charles , Fruth, Briant, LaPlant, Betsy, Sullivan, Daniel M.

Mayo Clinic

Journal of Clinical Oncology | March 11, 2020 | Volume: 30 | Issue: 15_suppl | Pages: 8013-8013

10.1200/jco.2012.30.15_suppl.8013 Get It

8013 Background: Obatoclax mesylate (GX15-070MS) is a BH3 mimetic that inhibits Bcl-2 protein family members including MCL-1, a dominant target in myeloma (MM). Obatoclax (OBX) inhibited viability of 14 MM cell lines (mean IC50 215 nM) and primary MM samples while exhibiting pre clinical synergy with bortezomib (BTZ). Sensitivity correlated with basal levels of Mcl-1 and Bcl-XL, but not Bcl2, Bim, Bax or Bak expression. Methods: We report a phase I trial of OBX in combination with BTZ. Eligibility required measureable disease, > 1 prior MM therapy, ≤10 cycles of prior BTZ and did not progress on prior BTZ therapy, creatinine ≤2 ULN. Starting dose level 1 was OBX 14 mg/m2 24-hour continuous iv. infusion days 1, 8, 15 of a 21-day cycle. BTZ given at 1.3mg/m2 iv. days 1, 4, 8 and 11. After protocol amendment OBX level 1 dosing was 30 mg/m2, level 2 was 40 mg/m2 IV both by continuous 3 hour infusion days 1, 8 and 15 on a 21 day schedule. Pre med. with famotidine was required. Results: Eleven patients were accrued, median age 62 (range: 46-77), median time from diagnosis was 4.7 years. Median of 2.5 cycles (range: 1-10). Median follow-up for patients still alive is 11.6 months (range: 0.9-35.5). At dose level 1, there were 2 DLTs. After amendment 8 patients were accrued (3 hour infusion): 4 at amended dose level 1 and 4 at dose level 2. All patients are now off treatment. 10 patients are evaluable for response: 2 patients at original dose level 1 (2 PR), 3 patients at dose level 1 (2 PR, 1 MR), no patients at dose level 2 responded: overall PR of 40%, clinical benefit response in 50% (95% CI: 19-81%). 6 patients had disease progression and 2 patients died. 4 DLTs were seen: at original dose level 1 grade 4 thrombocytopenia and delay of therapy > 15 days. At dose level 2, 1 patient had grade 3 somnolence, a 2nd patient grade 3 euphoria and grade 4 thrombocytopenia. No DLTs were seen at amended dose level 1. Common adverse events of any grade included GI, hematologic and neurologic e.g. euphoria, decreased level of consciousness, psychosis, speech. Conclusions: In summary MTD is OBX 30mg/m2 by 3 hour iv infusion once weekly, BTZ 1.3 mg/m2 days 1,4,8, and 11. Major toxicities were central neurologic and hematologic. This P2C consortium study was supported by NCI N01-CM62205.
Randomized trial of oral cyclophosphamide (C) with or without veliparib (V), an oral poly (ADP-ribose) polymerase (PARP) inhibitor, in patients with recurrent BRCA-positive ovarian, or primary peritoneal or high-grade serous ovarian carcinoma.
Sullivan, Daniel M. , Gandara, David R., Erlichman, Charles , Villalona‐Calero, Miguel A. , Morgan, Robert J. , Chen, Alice P. , Ji, Jiuping Jay, Lih, Chih‐Jian, Steinberg, Seth M. , Conley, Barbara A. , Doroshow, James H. , Kummar, Shivaani , Oza, Amit M. , Fleming, Gini F. , Ji, Jiuping , Allen, Deborah Emma , Williams, P. Mickey

Mayo Clinic

Journal of Clinical Oncology | March 11, 2020 | Volume: 30 | Issue: 15_suppl | Pages: 5020-5020

10.1200/jco.2012.30.15_suppl.5020 Get It

5020 Background: V+C was well tolerated in a phase I trial and responses and prolonged disease stabilization were observed in BRCA + patients (pts).To assess the relative contribution of the PARP inhibitor to the efficacy observed for the combination, we conducted a randomized multicenter trial comparing the response rate (RR) of V and C to the RR of C alone in patients with deleterious BRCA mutations and recurrent ovarian, or primary peritoneal, fallopian tube or high-grade serous ovarian cancer. Methods: Pts were ≥ 18 yrs, KPS ≥ 70%, had adequate organ function, prior therapy with PARP inhibitors was allowed.Both drugs were administered orally qd; C 50 mg, V 60 mg; 21 day cycles. Pts were randomized to receive either C alone or V+C. At disease progression, pts on C alone were allowed to cross over to the combination. Radiologic imaging was performed at baseline and q 3 cycles for assessment of response. Dose reduction of V was allowed to 40 mg for gr 3 non-hematologic or gr 4 hematologic toxicities. The study design had an 88% power to detect the difference between a 15% RR for C alone versus 35% for V+C, early closure if fewer responses were observed on the combination arm in the first 65 pts enrolled (half of the total projected accrual). Results: Total of 74 pts were enrolled (36 pts C, 38 pts V+C), median age 58 (37-79 yrs), # of prior therapies: median 4 (1-9), 2 pts had prior PARP therapy. Treatment was well tolerated, Gr ≥ 2 toxicities per arm for initial regimen (# of pts): C alone: lymphopenia (2), mucositis (1); V+C: lymphopenia (4), anemia (2), leucopenia (2), neutropenia (2). Of the 74 pts evaluable for response at the interim analysis, 3 PRs observed in 36 pts on V+C and 5 PRs of 38 pts on C alone arm; thus accrual was stopped. PAR levels assessed by validated ELISA were inhibited (>80%) in PBMCs in 9/10 pts 4 hours post V, no inhibition with C alone. Conclusions: Addition of V, a PARP inhibitor, to C did not improve RR versus C alone. Exomic sequencing, gene expression studies, and Fanconi Anemia triple stain immunofluorescence (FATSI) assay for FancD2 nuclear foci formation using archival tissue are ongoing.
A multicenter phase II study of bevacizumab (B) and temsirolimus (T) in women with recurrent epithelial ovarian cancer (OC): A study of the Mayo, Chicago, California, New York, Southeast, and Princess Margaret Phase II Consortia.
Morgan, Robert J. , Qin, Rui , Fruth, Briant, Hirte, Hal W. , Mackay, Helen , Tsoref, Daliah , Strevel, Elizabeth L., Welch, Stephen , Sullivan, Daniel M. , Wenham, Robert M. , Brewer, Molly, Chen, Helen X., Doyle, L. Austin, Gandara, David R., Einstein, Mark H. , Erlichman, Charles , Oza, Amit M. , Fleming, Gini F. , Sparano, Joseph A.

Mayo Clinic

Journal of Clinical Oncology | March 11, 2020 | Volume: 31 | Issue: 15_suppl | Pages: 5517-5517

10.1200/jco.2013.31.15_suppl.5517 Get It

5517 Background: Anti-angiogenic therapy is active in OC; the combination of VEGF and mTOR inhibitors is hypothesized to further improve activity. This report is the OC cohort of a multi-histology phase II study assessing the activity and toxicity of B/T. Methods: Patients (Pts) with recurrent epithelial OC who had received ≤ 2 chemotherapy regimens and no prior treatment with a VEGF or mTOR inhibitor were eligible. A two-stage design was used with second stage accrual if >6 pts had objective responses (OR) or >10 pts of the first 25 remained progression-free (PF) at six months (mo). Pre-defined end-points for a recommendation for further clinical trial evaluation included at least 15/50 with OR or 26/50 PF at six mo. Treatment included T 25 mg IV wkly and B 10 mg/kg IV q14 days on 28 day cycles. Results: 58 pts were enrolled (the first 50 pts are used to determine a final recommendation). Median age=62 (range 35-82). A median of 4 (range 1-23) cycles were administered. 24 were platinum-sensitive, 34 resistant. Off-study reasons included 13 adverse events and disease progression in 38. 3 refused further therapy due to toxicity. 14 of the first 50 pts had partial response (PR) (9 platinum-resistant); 25/50 remained PF (8 PR, 15 SD, 2 non-progressing) at 6 mo. Grade (gr) 3/4 toxicities occurring >2 events include: fatigue (4), stomatitis (7), hypertension (5), neutropenia (4), thrombocytopenia (4), hypokalemia (3). One rectal and one vaginal fistula, and two colonic perforations (one gr 2 and one gr 3 during cycles 3 and 1 respectively) were observed. Episodes of gr 1/2 oral, nasal, pulmonary, vaginal and gastrointestinal hemorrhage were also observed. Conclusions: Although the OR and PFS did not reach pre-defined standards, the numbers of OR and 6 mo PFS suggest potential enhanced activity with a combination of mTOR inhibitor with anti-angiogenic therapy. Other combinations of these targeted agents may result in more satisfactory activity with less toxicity. N01-CM-62203 (PMH) N01-CM-62208 (Southeast Phase 2) N01 CM-62209 (CCCP) N01-CM-62204 (NYCC) N01-CM-2011-0071C (Chicago) N01-CM62205 (Mayo) Clinical trial information: NCT01010126.
Challenges with Implementing the Centers for Disease Control and Prevention Opioid Guideline: A Consensus Panel Report
Kroenke, Kurt , Argoff, Charles E. , Canlas, Bernard, Covington, Edward C. , Frank, Joseph W. , Haake, Karl J, Hanling, Steven , Hooten, W. Michael , Kravitz, Richard L. , Krebs, Erin E. , Stanos, Steven P., Alford, Daniel P. , Kertesz, Stefan G. , Sullivan, Mark Daniel

Mayo Clinic

Pain Medicine | December 15, 2018 | Volume: 20 | Issue: 4 | Pages: 724-735

10.1093/pm/pny307 | PMID 30690556 Get It

Workshop on imaging science development for cancer prevention and preemption
Kelloff, Gary J. , Sullivan, Daniel C. , Baker, Houston, Clarke, Lawrence, Nordstrom, Robert J. , Tatum, James L. , Dorfman, Gary S., Berg, Christine D. , Birrer, Michael J. , Tempero, Margaret A. , Higley, Howard R., Petty, Brenda Gumbs, Sigman, Caroline C. , Ginsberg, Gregory G. , Dannenberg, Andrew J. , Hawk, Ernest T. , Messing, Edward M. , Grossman, H. Barton, Griebel, Donna, Henson, Donald E., Fabian, Carol J. , Zujewski, Jo Anne , Hayes, Wendy, Klein, Eric A. , Ocak, İclal , Tempany, Clare M. , Shtern, Faina, Parnes, Howard L. , Gómez, Jorge , Srivastava, Sudhir , Lam, Stephen , Seibel, Eric J. , Massion, Pierre P. , McLennan, Geoffrey, Burt, Randall W., Hoffman, John M. , El‐Deiry, Wafik S. , Papadimitrakopoulou, Vali, Veltri, Robert W., Solomon, Diane, Viner, Jaye L., Stratton, Steven P. , Rajadhyaksha, Milind , Dhawan, Atam P. , Jacobs, Paula , Pomper, Martin G. , Maley, Carlo C. , Sharma, Prateek , Wax, Adam , Harisinghani, Mukesh G. , Bigio, Irving J. , Ferrara, Katherine W. , Fantini, Sergio , Schnall, Mitchell D. , Zujewski, Jo Anne , Marzo, Angelo M. De , Ketterling, Jeffrey A. , Szabó, Éva , Cleary, Kevin , Suh, Robert D. , Pfeiffer, Ruth M. , Roy, Hemant K. , Wang, Thomas J. , Limburg, Paul J. , Hittelman, Walter N. , MacAulay, Calum E. , Jerónimo, José , Richards‐Kortum, Rebecca , Johnson, Karen A. , Klein, Eric A

Mayo Clinic

Cancer Biomarkers | January 31, 2017 | Volume: 3 | Issue: 1 | Pages: 1-33

10.3233/cbm-2007-3101 | PMID 17655039 Get It

A Randomized Phase II Study of Linsitinib (OSI-906) Versus Topotecan in Patients With Relapsed Small-Cell Lung Cancer
Otterson, Gregory A. , Dowlati, Afshin , Traynor, Anne M. , Horn, Leora , Ross, Helen J. , Hann, Christine L. , Hejleh, Taher Abu , Zhao, Xiuhua, Sullivan, Daniel M. , Chiappori, Alberto , Owonikoko, Taofeek Kunle , Nieva, Jorgé , Schell, Michael J.

Mayo Clinic

The Oncologist | September 30, 2016 | Volume: 21 | Issue: 10 | Pages: 1163-1164e

10.1634/theoncologist.2016-0220 | PMID 27694157 Get It

Abstract Lessons Learned Targeted therapy options for SCLC patients are limited; no agent, thus far, has resulted in a strategy promising enough to progress to phase III trials. Linsitinib, a potent insulin growth factor-1-receptor tyrosine kinase inhibitor, may be one agent with activity against SCLC. Despite lack of a reliable predictive biomarker in this disease, which may have partly contributed to the negative outcome reported here, linsitinib, although safe, showed no clinical activity in unselected, relapsed SCLC patients. Background. Treatment of relapsed small-cell lung cancer (SCLC) remains suboptimal. Insulin growth factor-1 receptor (IGF-1R) signaling plays a role in growth, survival, and chemoresistance in SCLC. Linsitinib is a potent IGF-1R tyrosine kinase inhibitor that potentially may be active against SCLC. Methods. In this phase II study, 8 eligible patients were randomly assigned in a 1:2 ratio to topotecan (1.5 mg/m2 intravenously or 2.3 mg/m2 orally, daily for 5 days for 4 cycles) or linsitinib (150 mg orally twice daily until progression). The primary endpoint was progression-free survival. Patients with relapsed SCLC, platinum sensitive or resistant, performance status (PS) 0–2, and adequate hematologic, renal, and hepatic function were enrolled. Patients with diabetes, cirrhosis, and those taking insulinotropic agents were excluded. Crossover to linsitinib was allowed at progression. Results. Fifteen patients received topotecan (8 resistant, 3 with PS 2) and 29 received linsitinib (16 resistant, 5 with PS 2). Two partial responses were observed with topotecan. Only 4 of 15 patients with topotecan and 1 of 29 with linsitinib achieved stable disease. Median progression-free survival was 3.0 (95% confidence interval [CI], 1.5–3.6) and 1.2 (95% CI, 1.1–1.4) months for topotecan and linsitinib, respectively (p = .0001). Median survival was 5.3 (95% CI, 2.2–7.6) and 3.4 (95% CI, 1.8–5.6) months for topotecan and linsitinib, respectively (p = .71). Grade 3/4 adverse events (>5% incidence) included anemia, thrombocytopenia, neutropenia/leukopenia, diarrhea, fatigue, dehydration, and hypokalemia for topotecan; and thrombocytopenia, fatigue, and alanine aminotransferase/aspartate aminotransferase elevations for linsitinib. Conclusion. Linsitinib was safe but showed no clinical activity in unselected, relapsed SCLC patients.
Statewide Cancer Clinical Trial Navigation Service
Moffitt, Karen, Brogan, F. A., Brown, Clarence, Kasper, Michael, Rosenblatt, Joseph D. , Smallridge, Robert C., Kromrey, Jeffrey D., Sullivan, Daniel

Mayo Clinic

Journal of Oncology Practice | May 14, 2010 | Volume: 6 | Issue: 3 | Pages: 127-132

10.1200/jop.200006 | PMID 20808555 Get It

Realizing education and awareness are paramount in making clinical trials available, the authors sought to evaluate a statewide navigation service to identify how it might improve cancer clinical trial accessibility in Florida for physicians and patients.
Understanding Why Patients Delay Seeking Care for Acute Coronary Syndromes
Ciechanowski, Paul , Russo, Joan , Soine, Laurie A., Jordan-Keith, Kier, Ting, Henry H. , Caldwell, James H., Sullivan, Mark Daniel

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | April 29, 2009 | Volume: 2 | Issue: 3 | Pages: 148-154

10.1161/circoutcomes.108.825471 | PMID 20031831 Get It

Background— Better insight into the psychosocial factors associated with prehospital delays in seeking care for acute coronary syndromes is needed to inform the design of future interventions. Delay in presenting for care after the onset of symptoms is common, limits the potential benefit of acute reperfusion, and has not been reduced by interventions tested thus far. Methods and Results— Seven hundred ninety-six patients with suspected ischemic heart disease scheduled for clinically indicated imaging stress tests completed questionnaires concerning psychological distress and attachment styles (worthiness to receive care, trustworthiness of others to provide care). The primary dependent variable for this study was response to a question from the rapid early action for coronary treatment trial concerning intention to “wait until very sure” before seeking care for a possible “heart attack.” Responses to this question were strongly associated with actual emergency department-reported and self-reported care delay in the rapid early action for coronary treatment trial. In multivariable ordinal regression models, a more negative view of the trustworthiness of others, greater physical limitations from angina, and no previous revascularization were independently associated with increased intention to wait to seek care for a myocardial infarction. Intention to wait was not associated with inducible ischemia or self-perceived risk of myocardial infarction. Conclusions— Intention to delay seeking care for acute coronary syndromes is associated with a patient’s view of the trustworthiness of others, previous experience with revascularization, and functional limitations, even after adjustment for objective and perceived acute coronary syndromes risk. These findings provide insight into novel factors contributing to longer delay times and may inform future interventions to reduce delay time.